

# **Total Synthesis of the Neuronal Cell-Protecting Carbazole Alkaloids** Carbazomadurin A and (S)-(+)-Carbazomadurin B

Yuhzo Hieda,<sup>[a]</sup> Tominari Choshi,\*<sup>[a]</sup> Haruto Fujioka,<sup>[a]</sup> and Satoshi Hibino\*<sup>[a]</sup>

Keywords: Total synthesis / Alkaloids / Nitrogen heterocycles / Electrocyclic reactions / Cross-coupling / Configuration determination

The total syntheses of the neuronal cell-protecting carbazole alkaloids carbazomadurin A and (S)-(+)-carbazomadurin B were achieved. The key step of the synthesis of the polysubstituted carbazole rings included an allene-mediated electrocyclic reaction of the  $6\pi$ -electron system that involved the indole 2,3-bond. The cleavage of the alkoxy groups of the resulting 3-ethoxy-8-isopropoxycarbazole successfully gave the 3,8-dihydroxycarbazole, which was converted into the

## Introduction

Carbazole alkaloids have attracted much interest among synthetic organic chemists because of their broad range of biological activities.<sup>[1,2]</sup> Since 1979, several groups have found new types of highly substituted carbazole alkaloids from different natural resources.<sup>[1,2]</sup> In 1997, the structurally unique carbazole alkaloids carbazomadurin A (1a) and B (1b, see Figure 1) were isolated by Seto and co-workers from the microorganism Actinomadura madurae 2808-SV1.<sup>[3]</sup> These alkaloids exhibit strong neuronal cell-protecting activities against cell death, which is induced by L-glutamate.<sup>[3]</sup> On the basis of their spectroscopic data, the structures of both alkaloids were determined to have the new 3.8-dioxygenated and highly functionalized carbazole framework. The absolute configuration of (+)-carbazomadurin B (1b), however, remained unknown.<sup>[3]</sup> In 2003, the first total synthesis of carbazomadurin A (1a) was reported by the Knölker group, which used a palladium-catalyzed sequence of the Buchwald-Hartwig amination, an oxidative cyclization, and a Stille coupling reaction.<sup>[4]</sup> A few years later, the same group reported the first enantioselective total synthesis of (+)-carbazomadurin B (1b), and the stereogenic center at the C-11 position was assigned as having the S configuration.<sup>[5]</sup>

[a] Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama, Hiroshima 729-0292, Japan E-mail: choshi@fupharm.fukuyama-u.ac.jp

hibino@fupharm.fukuyama-u.ac.jp

3,8-bis(OSEM)-carbazole (SEM = 2-trimethylsilylethoxymethyl). A Suzuki-Miyaura cross-coupling reaction of the 3,8-bis(OSEM)-carbazole with the corresponding alkenyl pinacol borates afforded the 1-alkenylcarbazoles, which were treated with tetra-n-butylammonium fluoride (TBAF) followed by reduction with NaBH<sub>4</sub> to provide carbazomadurin A and (S)-(+)-carbazomadurin B, respectively.



Figure 1. Carbazomadurins A (1a) and B (1b).

We are interested in the syntheses of bioactive nitrogencontaining fused heteroaromatic compounds, which includes natural products, through the employment of a thermal electrocyclic reaction that uses either a  $6\pi$ - or an aza  $6\pi$ -electron system and in principle involves an aromatic or heteroaromatic double bond.<sup>[6]</sup> Among these, we have reported the total syntheses of the hyellazoles, carazostatin, the carbazoquinocins,<sup>[7]</sup> murrayaquinone, furocarbazole, carbazomycin G<sup>[8]</sup> the calothrixins<sup>[9]</sup> mukonine<sup>[10]</sup> and the carquinostatins<sup>[11]</sup> by using an allene-mediated thermal electrocyclic reaction that involves the indole 2,3-bond. Recently, we reported a new total synthesis of carbazomadurin A (1a) by using our methodology through the construction of a highly substituted carbazole framework.<sup>[12]</sup> Herein, we describe the detailed total synthesis of carbazomadurin A (1a) and a new asymmetric total synthesis of (S)-(+)-carbazomadurin B (1b). Our synthetic strategy for 1a and 1b is illustrated by the retrosynthetic analysis in Scheme 1, in which the 1,3,8-trioxygenated carbazole framework 2 is obtained from 2-allenylindole intermediate 4 that is generated from 2-propargylindole 5. Furthermore, we plan to introduce an alkenyl side chain with the E con-

Homepage: www.fukuyama-u.ac.jp Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/ejoc.201301059.

figuration at the C-1 position of 1 through a Suzuki–Miyaura reaction<sup>[13]</sup> with alkenyl pinacol borates **3**.



Scheme 1. Retrosynthetic analysis of carbazomadurines A and B (MOM = methoxymethyl).

## **Results and Discussion**

To synthesize the initially required 7-oxygenated 2,3,4,7tetrasubstituted indoles 6a and 6b, we chose known ethyl 7-alkoxyindole-2-carboxylates 7a and  $7b^{[14]}$  as the starting materials (see Scheme 2). The treatment of 7a or 7b with  $\alpha,\alpha$ -dichloromethyl methyl ether in the presence of TiCl<sub>4</sub><sup>[15]</sup> gave 4-formylindoles 8a and 8b, respectively. The formyl groups of 8a and 8b were subsequently reduced with NaBH<sub>4</sub> to give the hydroxymethyl groups of 9a and 9b, which were treated with chloromethyl methyl ether (MOMCl) in the presence of N.N-diisopropylethylamine (*i*Pr<sub>2</sub>NEt) to yield MOM ethers **10a** and **10b**. The reduction of the ester groups of 10a and 10b by treatment with Red-Al in toluene followed by oxidation of the resulting alcohols 11a and 11b with MnO<sub>2</sub> afforded indole-2-carbaldehydes 12a and 12b. Further treatment of 12a or 12b with  $I_2$  gave the two required 7-oxygenated-2,3,4,7-tetrasubstituted indoles **6a** (67% yield from **7a**) and **6b** (57% yield from **7b**), respectively.



Scheme 2. Reagents and conditions: (a)  $Cl_2CHOCH_3$ ,  $TiCl_4$  (1 M),  $CH_2Cl_2$ , -10 °C, 4 h, **8a** (89%), **8b** (86%); (b) NaBH<sub>4</sub>, EtOH, 0 °C, 3 h, **9a** (99%), **9b** (99%); (c) MOMCl, *i*Pr<sub>2</sub>NEt,  $CH_2Cl_2$ , 0 °C to room temp., 5 h, **10a** (97%), **10b** (86%); (d) 65% Red-Al, toluene, 0 °C, 3 h, **11a** (99%), **11b** (99%); (e) MnO<sub>2</sub>,  $CH_2Cl_2$ , room temp., 12 h, **12a** (87%), **12b** (84%); (f) KOH, I<sub>2</sub>, *N*,*N*-dimethylformamide (DMF), 0 °C, 12 h, **6a** (91%), **6b** (94%).

We then synthesized 1,3,8-trioxygenated 1,2,3,5,8-pentasubstituted carbazoles 19a and 19b from 2,3,4,7-tetrasubstituted indoles 6a and 6b (see Scheme 3). The Stille coupling reaction of 3-iodoindoles 6a and 6b with tributyl(2-ethoxyvinyl)stannane<sup>[16]</sup> in the presence of PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> gave 3alkenylindoles 13a (E/Z, 1:3) and 13b (E/Z, 1:3), respectively. The Grignard reaction of 13a and 13b with ethynylmagnesium bromide followed by treatment of the resulting alcohols 14a and 14b with MOMCl and iPr2NEt produced MOM propargyl ethers 15a (E/Z, 1:3) and 15b (E/Z, 1:3)corresponding to 5. We subjected 15a and 15b to an allenemediated thermal electrocyclic reaction<sup>[6-12]</sup> using tetra-nbutylammonium fluoride (TBAF) in tetrahydrofuran (THF) according to our reported method<sup>[8b]</sup> to provide the desired carbazoles 16a and 16b corresponding to 2, respectively, in somewhat low yields. The oxidation of 16a and 16b with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDO) afforded 5-formylcarbazoles 17a and 17b, which were treated with 4 M HCl in THF to yield the 1-hydroxycarbazoles 18a and 18b. The sequential treatment of 18a and **18b** with *N*-phenyl-bis(trifluoromethanesulfonimide) (PhNTf<sub>2</sub>) and NaH gave the corresponding triflates 19a (10.4% yield from 7a in 13 steps) and 19b (8.5% from 7b in 13 steps). To prepare the 3,8-dihydroxycarbazole at the next stage, we attempted a cleavage of the 3,8-dialkoxy groups of 19a and 19b. Although treatment of 19a with



BBr<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub> gave only 3-hydroxycarbazole **20a** (60%), the treatment of **19b** with BBr<sub>3</sub> successfully gave 3,8-dihydroxycarbazole **20b**. The hydroxy groups of compound **20b** were immediately protected by using 2-(trimethylsilyl)ethoxymethyl chloride (SEMCl) and *i*Pr<sub>2</sub>NEt to produce 3,8-bis(OSEM)-carbazole **21** (97% from **19b**).



Scheme 3. Reagents and conditions: (a) tributyl(2-ethoxyvinyl)stannane,  $PdCl_2(PPh_3)_2$ ,  $Et_4NCl$ , DMF, 80 °C, 2 h, **13a** (77%), **13b** (86%); (b) ethynylmagnesium bromide, THF, 0 °C or -30 °C, 1 h, **14a** (97%), **14b** (81%); (c) MOMCl, *i*Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 50 °C, 12 h, **15a** (80%), **15b** (81%); (d) TBAF, THF, 80 °C, 6 h, **16a** (40%), **16b** (40%); (e) DDQ, CH<sub>2</sub>Cl<sub>2</sub>, room temp., 20 min, **17a** (95%), **17b** (73%); (f) HCl (4 M), ethylene glycol, THF, 50 °C, 30 min, **18a** (89%), **18b** (91%); (g) PhNTf<sub>2</sub>, NaH, THF, 0 °C, 30 min, **19a** (77%), **19b** (99%); (h) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, -78 °C to room temp., 3 h, **20a** (60%), **20b** (99%); (i) SEMCl, *i*Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to room temp., 12 h, 98%.

However, to introduce the (*E*)-alkenyl side chain, which is found at the C-1 position of carbazomadurins A (1a) and B (1b), pinacol borates 3a and 3b were prepared from commercially available 5-methyl-1-hexyne (22a) and known (*S*)-(+)-5-methyl-1-heptyne (22b), respectively, { $[a]_D = +15.3$ (CHCl<sub>3</sub>)}<sup>[5,17]</sup> in two steps (see Scheme 4). The zirconiumcatalyzed carboalumination of **22a** and **22b** by treatment with trimethylaluminum in the presence of zirconocene dichloride, according to the reported procedure by Negishi,<sup>[18]</sup> followed by the addition of I<sub>2</sub> afforded (*E*)-alkenyl iodides **23a** (78%) and **23b** (58%).<sup>[4,5]</sup> A subsequent Suzuki– Miyaura reaction<sup>[13]</sup> of **23a** and **23b** with bis(pinacolato)diboron in the presence of PdCl<sub>2</sub>(dppf) afforded pinacol borates **3a** (48%) and **3b** (53%, [*a*]<sub>D</sub> = +26.5), respectively.



Scheme 4. Reagents and conditions: (a) (1) Me<sub>3</sub>Al, Cp<sub>2</sub>ZrCl<sub>2</sub> (Cp = cyclopentadienyl), 1,2-dichloroethane, room temp., 12 h; (2) I<sub>2</sub>, THF, 0 °C to room temp., 1 h, **23a** (79%), **23b** (58%); (b) bis-(pinacolato)diboron, KOAc, PdCl<sub>2</sub>(dppf), dimethyl sulfoxide (DMSO), 80 °C, 2 h, **3a** (48%), **3b** (53%).

As shown in Scheme 5, triflates 19a and 19b were subjected to a Suzuki-Miyaura cross-coupling reaction<sup>[13]</sup> with alkenyl pinacol borates 3a in the presence of Pd(PPh<sub>3</sub>)<sub>4</sub> and Na<sub>2</sub>CO<sub>3</sub> to give 1-alkenylcarbazoles 24a (96%) and 24b (99%), respectively, in excellent yields. The treatment of 24a or 24b with BBr<sub>3</sub> to cleave the two ether bonds, however, did not provide the expected 3,8-dihydroxycarbazole 27a. On the other hand, the cross-coupling reaction of the triflate 21 with 3a or 3b in the presence of Na<sub>2</sub>CO<sub>3</sub> and Pd(PPh<sub>3</sub>)<sub>4</sub> gave the corresponding 1-alkenylcarbazoles 25a (86%) and **25b** (83%,  $[a]_{D} = +7.1$ ), respectively. Although reduction of the formyl group of 25a afforded alcohol 26, the sequential treatment with TBAF did not provide carbazomadurin A (1a) as had been previously reported.<sup>[12]</sup> As a result, the cleavage of both SEM groups of 25a and 25b by using TBAF in hexamethylphosphoramide (HMPA) produced the expected 3,8-dihydroxycarbazole 27a (71%) and **27b** (67%,  $[a]_D = +20.0$ ), respectively. Finally, the reduction of 27a and 27b with NaBH<sub>4</sub> in MeOH provided the corresponding carbazomadurin A (1a, 70%) and (S)-(+)-carbazomadurin B (1b, 78%). The spectral and physical data of synthetic carbazomadurin A (1a) and (+)-carbazomadurin B (1b) were identical with those of the reported data.<sup>[3–5]</sup> The value for the specific rotation of our synthetic (+)-carbazomadurin B (1b) was  $[a]_D = +13.1$  (c = 0.05, MeOH), which is consistent with the value  $[a]_D = +13.0$  (c = 0.05, MeOH) that was reported by the Knölker group.<sup>[5]</sup> This value of specific rotation was higher than that of natural (+)-carbazomadurin B {1b,  $[a]_D = +4$  (c = 0.05, MeOH)}.<sup>[3]</sup> The absolute configuration of 1b was S, as it was derived from known (S)-(+)-5-methyl-1-heptyne (**22b**).<sup>[17]</sup> The Knölker group<sup>[5]</sup> also assigned the S configuration to the stereogenic center of 1b.

# FULL PAPER



Scheme 5. Reagents and conditions: (a) **3a**, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 5 h, **24a** (96%), **24b** (99%); (b) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, -78 °C, 3 h; (c) **3a** or **3b**, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub> (3 M aqueous solution), DMF, 70 °C, 2 h, **25a** (86%), **25b** (83%); (d) diisobutylaluminum hydride (DIBAL-H), toluene, 0 °C, 1 h, 90%; (e) TBAF, THF, 80 °C, 1 h; (f) TBAF, HMPA, 100 °C, 1 h, **27a** (71%), **27b** (67%); (g) NaBH<sub>4</sub>, MeOH, room temp., 5 min, **1a** (70%), **1b** (78%).

# Conclusions

On the basis of these results, the known ethyl 7-isopropoxyindole-2-carboxylate (7b)<sup>[14]</sup> was a convenient starting material to realize our total syntheses of carbazomadurins A (1a) and B (1b). The 2,3,4,7-tetrasubstituted indole 6b was prepared from the indole 7b in six steps. The synthesis of functionalized carbazole 19b was achieved in seven steps from 6b through an allene-mediated electrocyclic reaction of the  $6\pi$ -electron system that involved the indole 2,3-bond. Carbazole 19b was converted into 3,8-bis(OSEM)-carbazole 21, which was subjected to a Suzuki-Miyaura crosscoupling reaction by treatment with alkenyl pinacol borates **3a** or **3b** to yield 1-alkenylcarbazoles **25a** and (+)-**25b**, respectively, The treatment of either 25a or (+)-25b with TBAF gave the desired 3,8-dihydroxycarbazoles 27a and (+)-27b, which were then reduced with NaBH<sub>4</sub> to provide carbazomadurin A (1a; 3.5% overall yields in 18 steps from 7b) and (S)-(+)-carbazomadurin B (1b; 3.3% overall yields in same number of steps from 7b), respectively. The physical and spectroscopic data of synthetic carbazomadurin A (1a) and (S)-(+)-carbazomadurin B (1b) were consistent with natural and synthetic carbazomadurins A (1a) and B (1b) in all respects.<sup>[3–5]</sup>

#### **Experimental Section**

General Methods: All nonaqueous reactions were carried out under nitrogen in dried glassware, unless otherwise noted. Solvents were dried and distilled according to standard protocols. Analytical thin layer chromatography was performed with silica gel  $60PF_{254}$ (Merck). Silica gel column chromatography was performed with silica gel 60N (63-210 µm, Kanto Chemical Co. Ltd.). All melting points were determined with a Yanagimoto micro melting point apparatus. The proton nuclear magnetic resonance (<sup>1</sup>H NMR) spectroscopic data were recorded with a JEOL AL-300 at 300 MHz and a JEOL JMN-LA500 at 500 MHz. Chemical shifts are reported relative to Me<sub>4</sub>Si ( $\delta$  = 0.00 ppm). The NMR spectroscopic data were recorded using CDCl<sub>3</sub>, unless otherwise noted. Multiplicities are indicated by s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and br. (broad). The carbon nuclear magnetic resonance (<sup>13</sup>C NMR) spectroscopic data were recorded with a JEOL AL-300 at 75 MHz and JEOL JMN-LA500 at 125 MHz. Chemical shifts are reported relative to  $CDCl_3$  ( $\delta = 77.0$  ppm) and  $[D_6]DMSO$  ( $\delta$  = 39.7 ppm). Infrared spectra were recorded using the attenuated total reflectance (ATR) method with a Shimadzu FTIR-8000 spectrophotometer and Technologies DuraScop. Low and high resolution mass spectra were recorded with JEOL JMS-700 spectrometers by using a direct inlet system. Optical rotations were measured with a JASCO P-2200 polarimeter.

Ethyl 4-Formyl-7-methoxyindole-2-carboxylate (8a): To a solution of ethyl 7-methoxyindole-2-carboxylate ( $7a^{[14]}$ , 1.0 g, 4.54 mmol) and  $\alpha$ , $\alpha$ -dichloromethyl methyl ether (1.24 mL, 13.62 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added dropwise TiCl<sub>4</sub> (1.5 mL, 13.62 mmol) at -10 °C. The mixture was stirred at the same temperature for 4 h and then was poured into ice water. The mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The CH<sub>2</sub>Cl<sub>2</sub> phase was washed with water and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10 g; EtOAc/hexane, 1:5 v/v) to give 4-formylindole 8a (1.0 g, 89%) as a pale yellow solid; m.p. 165-167 °C (acetone/hexane). IR (ATR): v = 1710, 1650 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 1.42 (t, J = 7.2 Hz, 3 H), 4.07 (s, 3 H), 4.42 (q, J = 7.2 Hz, 2 H), 6.83 (d, J =7.9 Hz, 1 H), 7.63 (d, J = 7.9 Hz, 1 H), 7.94 (d, J = 2.2 Hz, 1 H), 9.29 (br. s, 1 H), 10.06 (s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 14.4, 55.9, 61.3, 103.5, 109.1, 124.2, 125.9, 127.9, 129.6, 132.1,$ 151.5, 161.7, 191.2 ppm. MS (EI): m/z = 247 [M]<sup>+</sup>. HRMS (EI): calcd for C13H13NO4 247.0845; found 247.0849.

**Ethyl 4-Formyl-7-isopropoxyindole-2-carboxylate (8b):** The same procedure as above was carried out using ethyl 7-isopropoxyindole-2-carboxylate (**7b**<sup>[14]</sup>, 240 mg, 1.03 mmol),  $\alpha,\alpha$ -dichloromethyl methyl ether (0.28 mL, 3.11 mmol), and TiCl<sub>4</sub> (0.34 mL, 3.11 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (30 mL) to give 4-formylindole **8b** (230 mg, 86%) as a pale yellow solid; m.p. 134–137 °C (EtOAc). IR (ATR):  $\tilde{v} = 1706$ , 1654 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 1.42$  (t, J = 7.2 Hz, 3 H), 1.47 (d, J = 6.1 Hz, 6 H), 4.42 (q, J = 7.2 Hz, 2 H), 4.81–4.93 (m, 1 H), 6.80 (d, J = 8.1 Hz, 1 H), 7.60 (d, J = 8.1 Hz, 1 H), 7.92 (d, J = 2.4 Hz, 1 H), 9.31 (br. s, 1 H), 10.04 (s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 14.4$ , 22.0 (2×), 61.3, 71.2, 104.7, 109.1, 123.6, 126.0, 128.6, 129.4, 132.2, 150.0, 161.8, 191.1 ppm. MS (EI): m/z = 275 [M]<sup>+</sup>. HRMS (EI): calcd. for C<sub>15</sub>H<sub>17</sub>NO<sub>4</sub> 275.1158; found 275.1159.

Ethyl 4-Hydroxymethyl-7-methoxyindole-2-carboxylate (9a): To a solution of 4-formylindole 8a (100 mg, 0.40 mmol) in EtOH (4 mL) was added NaBH<sub>4</sub> (18.3 mg, 0.48 mmol) at 0 °C. The mixture was stirred at room temperature for 3 h and then was concentrated under reduced pressure. Water was added to the residue, and then the mixture was extracted with EtOAc. The EtOAc phase was washed

with water and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10 g; EtOAc/hexane, 1:4 v/v) to give the 4hydroxymethylindole **9a** (101 mg, 99%) as a white solid; m.p. 106– 107 °C (EtOAc/hexane). IR (ATR):  $\tilde{v} = 3320, 1700 \text{ cm}^{-1}$ . <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 1.42$  (t, J = 7.2 Hz, 3 H), 3.98 (s, 3 H), 4.41 (q, J = 7.2 Hz, 2 H), 4.92 (s, 1 H), 6.68 (d, J = 7.7 Hz, 1 H), 7.04 (d, J = 7.7 Hz, 1 H), 7.35 (d, J = 2.2 Hz, 1 H), 9.13 (br. s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 14.4, 55.5, 61.1, 63.7,$ 103.7, 107.2, 120.1, 126.7, 127.2, 127.3, 128.1, 146.4, 161.8 ppm. MS (EI):  $m/z = 249 \text{ [M]}^+$ . HRMS (EI): calcd. for C<sub>13</sub>H<sub>15</sub>NO<sub>4</sub> 249.1001, found 249.1015.

**Ethyl 4-Hydroxymethyl-7-isopropoxyindole-2-carboxylate (9b):** The same procedure as above was carried out using 4-formylindole **8b** (224 mg, 0.81 mmol) and NaBH<sub>4</sub> (37 mg, 0.98 mmol) in EtOH (8 mL) to give 4-hydroxymethylindole **9b** (224 mg, 99%) as a white solid; m.p. 132–134 °C (EtOAc). IR (ATR):  $\tilde{v} = 3460$ , 1680 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 1.39-1.44$  (m, 9 H), 4.40 (q, J = 7.2 Hz, 2 H), 4.66–4.79 (m, 1 H), 4.90 (s, 2 H), 6.66 (d, J = 7.7 Hz, 1 H), 7.01 (d, J = 7.7 Hz, 1 H), 7.33 (d, J = 2.5 Hz, 1 H), 9.16 (br. s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 14.4$ , 22.1 (2×), 61.1, 63.6, 70.5, 105.7, 107.2, 120.1, 126.4, 127.2, 127.3, 129.1, 144.5, 161.9 ppm. MS (EI): m/z = 277 [M]<sup>+</sup>. HRMS (EI): calcd. for C<sub>15</sub>H<sub>19</sub>NO<sub>4</sub> 277.1314; found 277.1284.

Ethyl 7-Methoxy-4-(methoxymethyloxy)methylindole-2-carboxylate (10a): To a solution of 4-hydroxymethylindole 9a (94 mg, 0.377 mmol) and MOMCl (0.03 mL, 0.45 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added dropwise *i*Pr<sub>2</sub>NEt (0.33 mL, 1.89 mmol) with cooling by an ice-water bath. The mixture was stirred at room temperature for 5 h and then was quenched with aqueous NH<sub>4</sub>Cl. The resulting mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The CH<sub>2</sub>Cl<sub>2</sub> phase was washed with water and brine, dried with Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10 g; EtOAc/hexane, 1:4 v/v) to give MOM ether 10a (127 mg, 97%) as a pale yellow solid; m.p. 82-83 °C (Et<sub>2</sub>O). IR (ATR):  $\tilde{v} = 1710 \text{ cm}^{-1}$ . <sup>1</sup>H NMR (300 MHz,  $CDCl_3$ ):  $\delta = 1.41$  (t, J = 7.2 Hz, 3 H), 3.44 (s, 3 H), 3.97 (s, 3 H), 4.40 (q, J = 7.2 Hz, 2 H), 4.72 (s, 2 H), 4.82 (s, 2 H), 6.67 (d, J =7.7 Hz, 1 H), 7.04 (d, J = 7.7 Hz, 1 H), 7.32 (d, J = 2.2 Hz, 1 H), 9.13 (br. s, 1 H) ppm. <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 14.4, 55.4, 55.5, 61.0, 67.3, 95.4, 103.7, 107.5, 121.4, 123.5, 127.3, 127.8, 128.1,146.5, 161.8 ppm. MS (EI): m/z = 293 [M]<sup>+</sup>. HRMS (EI): calcd. for C<sub>15</sub>H<sub>19</sub>NO<sub>5</sub> 293.1263; found 293.1277.

**Ethyl 7-Isopropoxy-4-(methoxymethyloxy)methylindole-2-carboxylate (10b):** The same procedure as above was carried out using 4hydroxymethylindole **9b** (750 mg, 2.70 mmol), MOMCI (0.25 mL, 3.24 mmol), and *i*Pr<sub>2</sub>NEt (2.34 mL, 13.52 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (30 mL) to give the oily MOM ether **10b** (720 mg, 86%). IR (ATR):  $\tilde{v} = 1700 \text{ cm}^{-1}$ . <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 1.39-1.44$  (m, 9 H), 3.45 (s, 3 H), 4.41 (q, J = 7.0 Hz, 2 H), 4.66–4.76 (m, 3 H), 4.82 (s, 2 H), 6.66 (d, J = 7.9 Hz, 1 H), 7.01 (d, J = 7.9 Hz, 1 H), 7.31 (d, J = 2.2 Hz, 1 H), 9.15 (br. s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 14.4$ , 22.1 (2×), 55.4, 61.0, 67.3, 70.4, 95.4, 105.7, 107.4, 121.5, 123.1, 127.1, 128.0, 129.1, 144.6, 161.9 ppm. MS (EI):  $m/z = 321 \text{ [M]}^+$ . HRMS (EI): calcd. for C<sub>17</sub>H<sub>23</sub>NO<sub>5</sub> 321.1576; found 321.1570.

**2-Hydroxymethyl-7-methoxy-4-(methoxymethyloxy)methylindole** (11a): To a solution of MOM ether 10a (500 mg, 1.70 mmol) in dry toluene (10 mL) was added dropwise Red-Al (65% in toluene, 1.27 g, 4.09 mmol) with cooling by an ice-water bath. The mixture was stirred at room temperature for 2 h and then was poured into ice water. The mixture was filtered through a pad of Celite. The



filtrate was extracted with EtOAc. The EtOAc phase was washed with water and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 30 g; EtOAc/hexane, 1:1 v/v) to give the oily alcohol **11a** (417 mg, 99%). IR (ATR):  $\tilde{v} = 3290 \text{ cm}^{-1}$ . <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta = 3.44$  (s, 3 H), 3.95 (s, 3 H), 4.71 (s, 2 H), 4.80 (br. s, 2 H), 4.81 (br. s, 2 H), 6.50 (d, J = 2.2 Hz, 1 H), 6.59 (d, J = 7.7 Hz, 1 H), 7.00 (d, J = 7.7 Hz, 1 H), 8.69 (br. s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 55.3$ , 55.4, 58.7, 67.5, 95.2, 99.4, 101.6, 120.8, 121.8, 126.8, 128.5, 137.4, 146.0 ppm. MS (EI): m/z = 251 [M]<sup>+</sup>. HRMS (EI): calcd. for C<sub>13</sub>H<sub>17</sub>NO<sub>4</sub> 251.1158; found 251.1171.

**2-Hydroxymethyl-7-isopropoxy-4-(methoxymethyloxy)methylindole** (11b): The same procedure as above was carried out using MOM ether 10b (2.2 g, 6.69 mmol) and Red-Al (65% in toluene, 4.99 g, 16.06 mmol) in dry toluene (50 mL) to give the oily alcohol 11b (2.2 g, 99%). IR (ATR):  $\tilde{v} = 3200 \text{ cm}^{-1}$ . <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 1.40$  (d, J = 5.9 Hz, 6 H), 3.44 (s, 3 H), 4.66–4.81 (m, 7 H), 6.48 (d, J = 2.6 Hz, 1 H), 6.59 (d, J = 7.7 Hz, 1 H), 6.97 (d, J = 7.7 Hz, 1 H), 8.72 (br. s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 22.2$  (2×), 55.3, 58.7, 67.6, 70.2, 95.2, 99.4, 103.8, 120.9, 121.4, 127.8, 128.7, 137.3, 144.1 ppm. MS (EI): m/z = 279 [M]<sup>+</sup>. HRMS (EI): calcd. for C<sub>15</sub>H<sub>21</sub>NO<sub>4</sub> 279.1471; found 249.1459.

**7-Methoxy-4-(methoxymethyloxy)methylindole-2-carbaldehyde** (12a): A mixture of the alcohol 11a (400 mg, 1.69 mmol) and activated MnO<sub>2</sub> (733 mg, 8.44 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (40 mL) was stirred at room temperature for 12 h. The reaction mixture was filtered through a pad of Celite, and then the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 40 g; EtOAc/hexane, 2:8 v/v) to give aldehyde 12a (344 mg, 87%) as a pale yellow solid; m.p. 94–96 °C (Et<sub>2</sub>O/hexane). IR (ATR):  $\tilde{v} = 1660 \text{ cm}^{-1}$ . <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta = 3.45$  (s, 3 H), 3.97 (s, 3 H), 4.72 (s, 2 H), 4.84 (s, 2 H), 6.72 (d, J = 7.7 Hz, 1 H), 7.06 (d, J = 7.7 Hz, 1 H), 7.37 (d, J = 2.2 Hz, 1 H), 9.24 (br. s, 1 H), 9.84 (s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 55.5$ , 55.6, 67.2, 95.4, 105.3, 113.4, 121.8, 124.2, 127.7, 129.5, 135.6, 146.8, 181.9 ppm. MS (EI): m/z = 249 [M]<sup>+</sup>. HRMS (EI): calcd. for C<sub>13</sub>H<sub>13</sub>NO<sub>4</sub> 249.1001; found 249.1014.

**7-Isopropoxy-4-(methoxymethyloxy)methylindole-2-carbaldehyde** (12b): The same procedure as above was carried out using alcohol **11b** (2.3 g, 8.23 mmol) and activated MnO<sub>2</sub> (3.58 g, 41.13 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (40 mL) to give aldehyde **12b** (1.9 g, 84%) as a pale yellow solid; m.p. 78–80 °C (Et<sub>2</sub>O). IR (ATR):  $\tilde{v} = 1670 \text{ cm}^{-1}$ . <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 1.40$  (d, J = 6.1 Hz, 6 H), 3.45 (s, 3 H), 4.67–4.75 (m, 3 H), 4.83 (s, 2 H), 6.71 (d, J = 7.7 Hz, 1 H), 7.03 (d, J = 7.7 Hz, 1 H), 7.36 (d, J = 2.2 Hz, 1 H), 9.38 (br. s, 1 H), 9.83 (s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 22.1$  (2×), 55.5, 67.2, 70.6, 95.4, 107.3, 113.4, 121.9, 123.8, 127.8, 130.5, 135.5, 144.9, 182.0 ppm. MS (EI):  $m/z = 277 \text{ [M]}^+$  HRMS (EI): calcd for C<sub>15</sub>H<sub>19</sub>NO<sub>4</sub> 277.1314; found 277.1291.

**3-Iodo-7-methoxy-4-(methoxymethyloxy)methylindole-2-carbaldehyde (6a):** To a mixture of aldehyde **12a** (300 mg, 1.20 mmol) and KOH powder (81 mg, 1.44 mmol) in DMF (10 mL) was added a solution of I<sub>2</sub> (229 mg, 1.81 mmol) in DMF (10 mL) with cooling by an ice-water bath. The mixture was stirred at room temperature for 12 h and then was poured into a solution of NaHSO<sub>3</sub> (140 mg, 1.33 mmol), 28% NH<sub>3</sub> (10 mL), and water (10 mL). The mixture was extracted with EtOAc. The EtOAc phase was washed with water and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10 g; EtOAc/hexane, 1:5 v/v) to give 3-iodoindole **6a** (362 mg, 91%) as a pale yellow solid; m.p. 112–113 °C (EtOAc/ hexane). IR (ATR):  $\tilde{v} = 1660 \text{ cm}^{-1}$ . <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta = 3.45$  (s, 3 H), 3.96 (s, 3 H), 4.81 (s, 2 H), 5.11 (s, 2 H), 6.72 (d, J = 7.9 Hz, 1 H), 7.13 (d, J = 7.9 Hz, 1 H), 9.48 (br. s, 1 H), 9.85 (s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 55.7$ , 55.7, 65.1, 67.6, 95.5, 105.4, 124.2, 124.4, 127.5, 129.6, 133.4, 146.9, 183.5 ppm. MS (EI): *m/z* = 375 [M]<sup>+</sup>. HRMS (EI): calcd. for C<sub>13</sub>H<sub>14</sub>NO<sub>4</sub>I 374.9968; found 374.9951.

**3-Iodo-7-isopropoxy-4-(methoxymethyloxy)methylindole-2-carbaldehyde (6b):** The same procedure as above was carried out using aldehyde **12b** (2.5 g, 8.83 mmol), KOH powder (594 mg, 10.60 mmol), and I<sub>2</sub> (3.36 g, 13.25 mmol) to give 3-iodoindole **6b** (3.3 g, 94%) as a pale yellow solid; m.p. 88–89 °C (EtOAc). IR (ATR):  $\tilde{v} = 1670 \text{ cm}^{-1}$ . <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 1.40$  (d, J = 6.2 Hz, 6 H), 3.46 (s, 3 H), 4.66–4.78 (m, 1 H), 4.81 (s, 2 H), 5.10 (s, 2 H), 6.71 (d, J = 7.7 Hz, 1 H), 7.10 (d, J = 7.7 Hz, 1 H), 9.47 (br. s, 1 H), 9.85 (s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 22.0 (2\times)$ , 55.6, 65.1, 67.7, 70.8, 95.5, 107.3, 123.9, 124.3, 127.6, 130.5, 133.3, 145.0, 183.6 ppm. MS (EI):  $m/z = 403 \text{ [M]}^+$ . HRMS (EI): calcd. for C<sub>15</sub>H<sub>18</sub>NO<sub>4</sub>I 403.0281; found 403.0266.

3-Ethoxyvinyl-7-methoxy-4-(methoxymethyloxy)methylindole-2carbaldehyde (13a): A solution of tributyl(2-ethoxyvinyl)stannane (458 mg, 1.27 mmol) in dry DMF (20 mL) was added to a stirred suspension of 3-iodoindole 6a (350 mg, 1.06 mmol), Et<sub>4</sub>NCl (200 mg, 1.27 mmol), and PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (6 mg, 0.0093 mmol) in dry DMF (10 mL) at the room temperature, and then the mixture was heated at 80 °C for 2 h. After cooling the reaction to an ambient temperature, the mixture was quenched with aqueous 30% KF. The mixture was stirred at the same temperature for 30 min and then was filtered through a pad of Celite. The filtrate was extracted with EtOAc. The EtOAc phase was washed with water and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 5 g; EtOAc/ hexane, 2:8 v/v) to give the oily 3-alkenylindole 13a (310 mg, 77%). IR (ATR):  $\tilde{v} = 1650 \text{ cm}^{-1}$ . <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 1.26$ (t, J = 7.0 Hz, 9/4 H), 1.39 (t, J = 7.0 Hz, 3/4 H), 3.43 (s, 3 H),3.88-4.04 (m, 5 H), 4.70 (s, 6/4 H), 4.71 (s, 2/4 H), 4.87 (s, 2/4 H), 4.87 (s, 6/4 H), 5.89 (d, J = 7.0 Hz, 3/4 H), 6.36 (d, J = 12.5 Hz, 1/ 4 H), 6.42 (d, J = 7.0 Hz, 3/4 H), 6.62–6.71 (m, 5/4 H), 6.98–7.03 (m, 1 H), 9.04 (br. s, 1 H), 9.81 (s, 1/4 H), 10.0 (s, 3/4 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 14.7, 15.1, 55.4, 65.8, 66.7, 66.7, 68.5, 94.6, 94.8, 96.3, 96.5, 104.5, 105.1, 121.2, 123.0, 123.0, 124.3, 124.6, 125.3, 126.1, 126.5, 129.1, 129.2, 130.9, 131.9, 146.6, 146.7, 147.2, 151.6, 181.7, 183.8 ppm. MS (EI):  $m/z = 319 \text{ [M]}^+$ . HRMS (EI): calcd. for C<sub>17</sub>H<sub>21</sub>NO<sub>5</sub> 319.1420; found 319.1402.

3-Ethoxyvinyl-7-isopropoxy-4-(methoxymethyloxy)methylindole-2carbaldehyde (13b): The same procedure as above was carried out using 3-iodoindole 6b (606 mg, 1.50 mmol), Et<sub>4</sub>NCl (373 mg, 2.25 mmol), and PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (10 mg, 0.015 mmol) in dry DMF (10 mL) along with tributyl(2-ethoxyvinyl)stannane (814 mg, 2.25 mmol) in dry DMF (20 mL) to give the oily 3-alkenylindole **13b** (451 mg, 86%). IR (ATR):  $\tilde{v} = 1650 \text{ cm}^{-1}$ . <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 1.25$  (t, J = 7.0 Hz, 9/4 H), 1.36–1.42 (m, 27/4 H), 3.43 (s, 3 H), 3.91 (q, J = 7.0 Hz, 6/4 H), 4.01 (q, J = 7.0 Hz, 2/4 H), 4.65–4.73 (m, 3 H), 4.87 (s, 2 H), 5.89 (d, J = 7.2 Hz, 3/4 H), 6.36 (d, J = 12.5 Hz, 1/4 H), 6.41 (d, J = 7.2 Hz, 3/4 H), 6.62–6.70 (m, 5/4 H), 6.96-7.01 (m, 1 H), 9.09 (br. s, 1 H), 9.81 (s, 1/4 H), 10.04 (s, 3/4 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 14.7, 15.0, 21.9 (2×), 55.4, 65.8, 66.7, 66.7, 68.5, 70.3, 70.3, 94.6, 94.8, 96.4, 96.6, 106.5, 107.0, 121.3, 123.1, 123.1, 123.9, 124.1, 125.4, 126.3, 126.6, 130.1, 130.2, 130.8, 131.8, 144.7, 144.8, 147.2, 151.5, 181.7, 183.9 ppm. MS (EI):  $m/z = 347 [M]^+$ . HRMS (EI): calcd. for C<sub>19</sub>H<sub>25</sub>NO<sub>5</sub> 347.1733; found 347.1756.

3-Ethoxyvinyl-2-(1-hydroxyprop-2-yn-1-yl)-7-methoxy-4-(methoxymethyloxy)methylindole (14a): To a solution of 3-alkenylindole 13a (4.7 g, 14.6 mmol) in dry THF (30 mL) was gradually added ethynylmagnesium bromide (0.5 м in THF, 87.6 mL, 43.8 mmol) at 0 °C. After stirring the reaction at 0 °C for 1 h, the mixture was quenched with aqueous NH<sub>4</sub>Cl solution. The resulting mixture was extracted with EtOAc. The EtOAc phase was washed with brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 20 g; EtOAc/hexane, 3:17 v/v) to give the oily 2-propargyl alcohol 14a (4.9 g, 97%). IR (ATR):  $\tilde{v} = 3280 \text{ cm}^{-1}$ . <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 1.28$ (t, J = 7.0 Hz, 9/4 H), 1.36 (t, J = 7.0 Hz, 3/4 H), 2.65-2.67 (m, 1)H), 3.43 (s, 3 H), 3.85-4.01 (m, 5 H), 4.66-4.99 (m, 4 H), 5.69-5.73 (m, 1 H), 5.81 (d, J = 7.0 Hz, 3/4 H), 6.17 (d, J = 12.8 Hz, 1/4 H), 6.26 (d, J = 7.0 Hz, 3/4 H), 6.57-6.65 (m, 5/4 H), 6.97-7.05 (m, 1) H), 8.84 (br. s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 14.8, 14.9, 55.3, 55.3, 57.3, 65.1, 66.9, 67.0, 68.6, 74.4, 74.5, 81.3, 82.4, 94.5, 94.8, 97.5, 99.0, 101.9, 101.9, 108.3, 110.9, 122.3, 122.4, 122.6, 122.7, 126.3, 126.5, 126.9, 127.2, 133.4, 145.1, 146.2, 146.3 ppm. MS (EI):  $m/z = 345 \text{ [M]}^+$ . HRMS (EI): calcd. for C<sub>19</sub>H<sub>23</sub>NO<sub>5</sub> 345.1576; found 345.1588.

3-Ethoxyvinyl-2-(1-hydroxyprop-2-yn-1-yl)-7-isopropoxy-4-(methoxymethyloxy)methylindole (14b): The same procedure as above was carried out using 3-alkenylindole 13b (1.1 g, 3.17 mmol) and ethynylmagnesium bromide (0.5 M in THF, 18.9 mL, 9.49 mmol), which was added at -30 °C. The reaction mixture was then stirred at 0 °C for 1 h to give the oily 2-propargyl alcohol 14b (960 mg, 81%). IR (ATR):  $\tilde{v} = 3280 \text{ cm}^{-1}$ . <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$ = 1.28 (t, J = 7.0 Hz, 9/4 H), 1.36–1.42 (m, 27/4 H), 2.67 (d, J = 2.2 Hz, 3/4 H), 2.69 (d, J = 2.2 Hz, 1/4 H), 3.42 (s, 3 H), 3.84–3.97 (m, 2 H), 4.65–4.78 (m, 5 H), 5.72 (t, J = 2.6 Hz, 1 H), 5.81 (d, J= 7.0 Hz, 3/4 H), 6.16 (d, J = 12.8 Hz, 1/4 H), 6.26 (d, J = 7.0 Hz, 3/4 H), 6.57–6.63 (m, 5/4 H), 6.95 (d, J = 7.0 Hz, 1 H), 8.71 (br. s, 1/4 H), 8.75 (br. s, 3/4 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 14.8, 14.9, 22.1 (2×), 22.2 (2×), 55.2, 55.4, 57.2, 66.9, 68.7, 70.2, 70.3, 74.4, 74.5, 81.2, 82.4, 94.6, 94.9, 97.5, 99.1, 104.0, 105.5, 108.3, 110.8, 121.9, 122.7, 126.9, 127.3, 127.4, 133.1, 144.3, 144.4, 144.9, 145.0 ppm. MS (EI): m/z = 373 [M]<sup>+</sup>. HRMS (EI): calcd. for C<sub>21</sub>H<sub>27</sub>NO<sub>5</sub> 373.1889; found 373.1873.

3-Ethoxyvinyl-7-methoxy-2-{[1-(methoxymethyloxy)prop-2-yn-1yl]}-4-(methoxymethyloxy)methylindole (15a): To a mixture of propargyl alcohol 14a (546 mg, 1.56 mmol) and *i*Pr<sub>2</sub>NEt (1.35 mL, 7.82 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added chloromethyl methyl ether (0.35 mL, 4.69 mmol) with cooling by an ice-water bath, and then the mixture was heated at 50 °C for 12 h. After cooling the reaction to an ambient temperature, the mixture was quenched with aqueous NH<sub>4</sub>Cl. The resulting mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The CH<sub>2</sub>Cl<sub>2</sub> phase was washed with water and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10 g; EtOAc/hexane, 3:17 v/v) to give the oily propargyl ether 15a (492 mg, 80%). IR (ATR):  $\tilde{v} = 3274 \text{ cm}^{-1}$ . <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 1.30$ (t, J = 7.0 Hz, 9/4 H), 1.37 (t, J = 7.0 Hz, 3/4 H), 2.56 (d, J =2.2 Hz, 3/4 H), 2.63-2.66 (m, 1/4 H), 3.40 (s, 3 H), 3.43 (s, 3 H), 3.88-3.98 (m, 5 H), 4.63-5.03 (m, 6 H), 5.73 (d, J = 7.0 Hz, 3/4H), 5.85 (d, J = 2.2 Hz, 3/4 H), 6.13 (d, J = 12.7 Hz, 1/4 H), 6.23 (d, J = 7.0 Hz, 3/4 H), 6.55–6.61 (m, 5/4 H), 6.95–7.02 (m, 1 H), 8.65 (br. s, 1/4 H), 8.69 (br. s, 3/4 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 14.8, 15.2, 55.4, 55.8, 56.0, 56.4, 59.6, 60.3, 65.1, 66.9, 67.0, 68.3, 74.1, 75.4, 80.3, 80.7, 93.6, 93.6, 94.7, 95.0, 97.2, 97.7, 101.7, 102.0, 109.6, 111.8, 122.3, 122.6, 122.8, 126.6, 126.8, 127.1, 129.8, 130.6, 145.1, 146.2, 149.3 ppm. MS (EI):  $m/z = 389 \text{ [M]}^+$ . HRMS (EI): calcd. for C<sub>21</sub>H<sub>27</sub>NO<sub>6</sub> 389.1838; found 389.1841.

3-Ethoxyvinyl-7-isopropoxy-2-{[1-(methoxymethyloxy)prop-2-yn-1yl]}-4-(methoxymethyloxy)methylindole (15b): The same procedure as above was carried out using propargyl alcohol 14b (2.6 g, 6.88 mmol), *i*Pr<sub>2</sub>NEt (5.96 mL, 34.41 mmol), and MOMCl (1.57 mL, 20.64 mmol) to give the oily propargyl ether 15b (2.4 g, 81%). IR (ATR):  $\tilde{v} = 3280 \text{ cm}^{-1}$ . <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$ = 1.31 (t, J = 7.0 Hz, 9/4 H), 1.38–1.46 (m, 27/4 H), 2.59 (d, J = 2.2 Hz, 3/4 H), 2.66 (d, J = 2.2 Hz, 1/4 H), 3.41-3.43 (m, 6 H), 3.88-3.98 (m, 2 H), 4.65-4.97 (m, 7 H), 5.72-5.75 (m, 1 H), 5.86 (d, J = 2.2 Hz, 3/4 H), 6.14 (d, J = 12.8 Hz, 1/4 H), 6.23 (d, J =7.0 Hz, 3/4 H), 6.55–6.61 (m, 5/4 H), 6.94–7.00 (m, 1 H), 8.63 (s, 1/4 H), 8.67 (s, 3/4 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 14.8$ , 15.2, 22.1 (2×), 22.1 (2×), 55.3, 55.7, 56.0, 59.6, 60.3, 65.0, 66.9, 67.0, 68.2, 70.0, 70.1, 74.1, 75.3, 80.4, 80.7, 93.6, 93.6, 94.7, 95.0, 97.3, 97.8, 103.8, 104.0, 109.5, 111.7, 122.1, 122.3, 122.3, 126.9, 127.2, 127.5, 127.8, 129.7, 130.5, 144.2, 144.3, 145.0 ppm. MS (EI):  $m/z = 417 \text{ [M]}^+$ . HRMS (EI): calcd. for C<sub>23</sub>H<sub>31</sub>NO<sub>6</sub> 417.2151; found 417.2140.

3-Ethoxy-8-methoxy-1-methoxymethyloxy-5-(methoxymethyloxy)methyl-2-methylcarbazole (16a): To a solution of propargyl ether 15a (120 mg, 0.31 mmol) in dry THF (1 mL) was added TBAF (1 м in THF, 0.92 mL, 0.924 mmol) at room temperature, and then the mixture was heated at 80 °C for 6 h. After cooling the reaction to an ambient temperature, the mixture was quenched with water. The resulting mixture was extracted with EtOAc. The EtOAc phase was washed with water and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 30 g; EtOAc/hexane, 1:9 v/v) to give carbazole 16a (40 mg, 40%) as a yellow solid; m.p. 105-106 °C (EtOAc/hexane). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 1.48$  (t, J =7.0 Hz, 3 H), 2.33 (s, 3 H), 3.44 (s, 3 H), 3.75 (s, 3 H), 4.01 (s, 3 H), 4.15 (q, J = 7.0 Hz, 2 H), 4.76 (s, 2 H), 5.08 (s, 2 H), 5.23 (s, 2 H), 6.79 (d, J = 7.9 Hz, 1 H), 7.06 (d, J = 7.9 Hz, 1 H), 7.50 (s, 1 H), 9.25 (br. s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 9.8, 15.1, 55.5, 55.6, 57.1, 64.9, 67.9, 95.1, 98.6, 101.4, 104.5, 117.5, 120.6, 122.0, 123.1, 123.7, 127.1, 130.2, 142.0, 146.0, 151.9 ppm. MS (EI):  $m/z = 389 \text{ [M]}^+$ . HRMS (EI): calcd. for C<sub>21</sub>H<sub>27</sub>NO<sub>6</sub> 389.1838; found 389.1827.

**3-Ethoxy-8-isopropoxy-1-methoxymethyloxy-5-(methoxymethyloxy)methyl-2-methylcarbazole (16b):** The same procedure as above was carried out using propargyl ether **15b** (2.4 g, 5.63 mmol) and TBAF (1 m in THF, 16.9 mL, 16.9 mmol) to give carbazole **16b** (930 mg, 40%) as a pale yellow solid; m.p. 69–71 °C (Et<sub>2</sub>O). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 1.44$  (d, J = 6.1 Hz, 6 H), 1.49 (t, J =7.0 Hz, 3 H), 2.34 (s, 3 H), 3.46 (s, 3 H), 3.75 (s, 3 H), 4.15 (q, J =7.0 Hz, 2 H), 4.67–4.75 (m, 1 H), 4.78 (s, 2 H), 5.08 (s, 2 H), 5.23 (s, 2 H), 6.82 (d, J = 7.9 Hz, 1 H), 7.04 (d, J = 7.9 Hz, 1 H), 7.49 (s, 1 H), 9.28 (br. s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta =$ 9.8, 15.1, 22.3 (2×), 55.6, 57.0, 64.9, 67.9, 71.2, 95.1, 98.7, 101.5, 108.0, 117.5, 120.6, 122.0, 123.3, 123.7, 127.2, 131.6, 141.9, 144.1, 151.8 ppm. MS (EI): m/z = 417 [M]<sup>+</sup>. HRMS (EI): calcd. for C<sub>23</sub>H<sub>31</sub>NO<sub>6</sub> 417.2151; found 417.2151.

**3-Ethoxy-8-methoxy-1-methoxymethyloxy-2-methylcarbazole-5carbaldehyde (17a):** To a solution of carbazole **16a** (1.2 g, 3.08 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added DDQ (839 mg, 3.70 mmol) at room temperature, and the resulting mixture was stirred at that temperature for 20 min. The reaction mixture was filtered through a pad of Celite. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by column chromatography (silica gel, 40 g; EtOAc/hexane, 2:8 v/v) to give carbazole-5-carbaldehyde **17a** (1.0 g, 95%) as a pale yellow solid; m.p. 102–103 °C (EtOAc/hexane). IR (ATR):  $\tilde{v} = 1650 \text{ cm}^{-1}$ . <sup>1</sup>H



NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 1.50$  (t, J = 7.0 Hz, 3 H), 2.35 (s, 3 H), 3.76 (s, 3 H), 4.11 (s, 3 H), 4.25 (q, J = 7.0 Hz, 2 H), 5.23 (s, 2 H), 6.96 (d, J = 8.0 Hz, 1 H), 7.68 (d, J = 8.0 Hz, 1 H), 8.49 (s, 1 H), 9.55 (br. s, 1 H), 10.20 (s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 9.9$ , 15.0, 55.9, 57.1, 64.5, 98.7, 103.5, 104.1, 119.1, 121.9, 122.4, 125.7, 127.8, 130.1, 131.0, 141.7, 150.8, 151.7, 192.0 ppm. MS (EI): m/z = 343 [M]<sup>+</sup>. HRMS (EI): calcd. for C<sub>19</sub>H<sub>21</sub>NO<sub>5</sub> 343.1420; found 343.1419.

**3-Ethoxy-8-isopropoxy-1-methoxymethyloxy-2-methylcarbazole-5carbaldehyde (17b):** The same procedure as above was carried out using carbazole **16b** (2.3 g, 5.51 mmol) and DDQ (1.5 g, 6.61 mmol) to give carbazole-5-carbaldehyde **17b** (1.5 g, 73%) as a pale yellow solid; m.p. 130–131 °C (EtOAc). IR (ATR):  $\bar{v} =$ 1670 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 1.48-1.53$  (m, 9 H), 2.35 (s, 3 H), 3.75 (s, 3 H), 4.25 (q, *J* = 7.0 Hz, 2 H), 4.82–4.94 (m, 1 H), 5.22 (s, 2 H), 6.93 (d, *J* = 8.3 Hz, 1 H), 7.63 (d, *J* = 8.3 Hz, 1 H), 8.48 (s, 1 H), 9.55 (br. s, 1 H), 10.18 (s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 9.9$ , 15.1, 22.2 (2×), 57.0, 64.5, 71.2, 98.9, 103.6, 105.9, 119.2, 121.9, 122.5, 125.3, 128.0, 131.0, 141.7, 149.3, 151.6, 191.9 ppm. MS (EI): *m*/*z* = 371 [M]<sup>+</sup>. HRMS (EI): calcd. for C<sub>21</sub>H<sub>25</sub>NO<sub>5</sub> 371.1733; found 371.1720.

3-Ethoxy-1-hydroxy-8-methoxy-2-methylcarbazole-5-carbaldehyde (18a): To a mixture of 5-formylcarbazole 17a (940 mg, 2.74 mmol) and ethylene glycol (2 mL) in THF (20 mL) was added HCl (4 M solution, 2 mL) at room temperature. After stirring the reaction at 50 °C for 30 min, the mixture was cooled to an ambient temperature and then extracted with EtOAc. The EtOAc phase was washed with water and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10 g; EtOAc/hexane, 4:6 v/v) to give 1-hydroxycarbazole 18a (730 mg, 89%) as a pale yellow solid; m.p. 234-236 °C (EtOAc/hexane). IR (ATR):  $\tilde{v} = 3367, 1646 \text{ cm}^{-1}$ . <sup>1</sup>H NMR (300 MHz, [D<sub>6</sub>]DMSO):  $\delta$  = 1.42 (t, J = 7.0 Hz, 3 H), 2.19 (s, 3 H), 4.06–4.11 (m, 5 H), 7.17 (d, J = 8.1 Hz, 1 H), 7.78 (d, J =8.1 Hz, 1 H), 8.12 (s, 1 H), 8.99 (s, 1 H), 10.13 (s, 1 H), 10.85 (br. s, 1 H) ppm. <sup>13</sup>C NMR (300 MHz,  $[D_6]DMSO$ ):  $\delta = 9.2, 14.9, 55.9,$ 63.6, 98.4, 104.6, 111.6, 120.2, 121.1, 125.0, 125.3, 129.3, 131.0, 140.0, 150.7, 151.1, 192.0 ppm. MS (EI):  $m/z = 299 \text{ [M]}^+$ . HRMS (EI): calcd. for  $C_{17}H_{17}NO_4$  299.1158; found 299.1153.

**3-Ethoxy-1-hydroxy-8-isopropoxy-2-methylcarbazole-5-carbaldehyde (18b):** The same procedure as above was carried out using 5-formylcarbazole **17b** (411 mg, 1.11 mmol) and HCl (4 M solution, 2 mL) to give 1-hydroxycarbazole **18b** (329 mg, 91%) as a pale yellow solid; m.p. 207–209 °C (EtOAc). IR (ATR):  $\tilde{v} = 3320$ , 1650 cm<sup>-1.</sup> <sup>1</sup>H NMR (300 MHz, [D<sub>6</sub>]DMSO):  $\delta = 1.38$ –1.46 (m, 9 H), 2.18 (s, 3 H), 4.08 (q, J = 7.0 Hz, 2 H), 4.97–5.05 (m, 1 H), 7.16 (d, J = 8.1 Hz, 1 H), 7.72 (d, J = 8.1 Hz, 1 H), 8.12 (br. s, 1 H), 9.08 (br. s, 1 H), 10.10 (s, 1 H), 10.65 (s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, [D<sub>6</sub>]DMSO):  $\delta = 9.6$ , 15.3, 22.2, 31.0, 64.1, 71.2, 99.0, 106.5, 112.1, 120.7, 121.6, 124.9, 125.4, 130.3, 131.8, 140.2, 149.4, 151.5, 192.5 ppm. MS (EI): m/z = 327 [M]<sup>+</sup>. HRMS (EI): calcd. for C<sub>19</sub>H<sub>21</sub>NO<sub>4</sub> 327.1471; found 327.1484.

**3-Ethoxy-8-methoxy-2-methyl-1-(trifluoromethylsulfonyloxy)carbazole-5-carbaldehyde (19a):** To a stirred mixture of NaH (60%, 240 mg, 6.01 mmol) in THF (20 mL) was added 1-hydroxycarbazole **18a** (720 mg, 2.41 mmol) in THF (5 mL) with cooling by an ice-water bath. After stirring the resulting mixture at 0 °C for 10 min, Tf<sub>2</sub>NPh (992 mg, 2.65 mmol) was added to the reaction mixture at the same temperature. The stirring was continued at the same temperature for an additional 30 min, and then the mixture was quenched with aqueous NH<sub>4</sub>Cl. The resulting soluton was extracted with EtOAc. The EtOAc phase was washed with water and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10 g; EtOAc/hexane, 1:9 v/v) to give triflate **19a** (800 mg, 77%) as a pale yellow solid; m.p. 165–167 °C (EtOAc/hexane). IR (ATR):  $\tilde{v} = 1680, 1400, 1210 \text{ cm}^{-1}$ . <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 1.52$  (t, *J* = 7.0 Hz, 3 H), 2.42 (s, 3 H), 4.13 (s, 3 H), 4.29 (q, *J* = 7.0 Hz, 2 H), 7.02 (d, *J* = 8.3 Hz, 1 H), 7.73 (d, *J* = 8.3 Hz, 1 H), 8.59 (br. s, 1 H), 8.82 (s, 1 H), 10.14 (s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 10.3, 14.9, 56.0, 64.9, 105.1, 108.1, 116.6, 121.4, 121.6, 123.4, 125.7, 127.0, 130.6, 131.4, 132.5, 150.9, 151.6, 191.9 ppm. MS (EI): m/z = 431 [M]<sup>+</sup>. HRMS (EI): calcd. for C<sub>18</sub>H<sub>16</sub>F<sub>3</sub>NO<sub>6</sub>S 431.0650; found 431.0658.$ 

**3-Ethoxy-8-isopropoxy-2-methyl-1-(trifluoromethylsulfonyloxy)carbazole azole-5-carbaldehyde (19b):** The same procedure as above was carried out using NaH (60%, 37 mg, 0.92 mmol), 1-hydroxycarbazole **18b** (200 mg, 0.68 mmol) in THF (5 mL), and Tf<sub>2</sub>NPh (254 mg, 0.68 mmol) to give triflate **19b** (310 mg, 99%) as a pale yellow solid; m.p. 131–133 °C (EtOAc). IR (ATR):  $\tilde{v} = 1680$ , 1400, 1210 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 1.50-1.54$  (m, 9 H), 2.42 (s, 3 H), 4.28 (q, J = 7.0 Hz, 2 H), 4.87–4.95 (m, 1 H), 7.01 (d, J = 8.3 Hz, 1 H), 7.70 (d, J = 8.3 Hz, 1 H), 8.59 (br. s, 1 H), 8.82 (s, 1 H), 10.12 (s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 10.4$ , 14.9, 22.1 (2×), 64.8, 71.6, 106.6, 108.1, 121.2, 121.8, 123.4, 125.2, 126.9, 131.3, 131.5, 132.5, 149.4, 151.5, 191.9 ppm. MS (EI): *m/z* = 459 [M]<sup>+</sup>. HRMS (EI): calcd. for C<sub>20</sub>H<sub>20</sub>F<sub>3</sub>NO<sub>6</sub>S 459.0963; found 459.0966.

3-Hydroxy-8-methoxy-2-methyl-1-(trifluoromethylsulfonyloxy)carbazole-5-carbaldehvde (20a): To a solution of triflate 19a (50 mg, 0.12 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added BBr<sub>3</sub> (57 µL, 0.58 mmol) at -78 °C. After stirring at room temperature for 3 h, the reaction mixture was poured into ice water. The mixture was extracted with EtOAc. The EtOAc phase was washed with water and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10 g; EtOAc/hexane, 2:8 v/v) to give 3-hydroxycarbazole 20a (28 mg, 60%) as a pale yellow solid; m.p. 280-284 °C (EtOAc/hexane). IR (ATR):  $\tilde{v} = 3200$ , 1650 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta =$ 2.29 (s, 3 H), 4.11 (s, 3 H), 7.25 (d, J = 8.3 Hz, 1 H), 7.85 (d, J = 8.3 Hz, 1 H), 8.65 (s, 1 H), 9.78 (s, 1 H), 10.09 (s, 1 H), 11.61 (s, 1 H) ppm. <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 11.0, 56.3, 106.2, 110.0, 116.1, 118.9, 120.3, 123.3, 125.2, 126.9, 127.0, 131.0, 132.7, 148.9, 151.3, 192.4 ppm. MS (EI):  $m/z = 403 \text{ [M]}^+$ . HRMS (EI): calcd. for C<sub>16</sub>H<sub>12</sub>F<sub>3</sub>NO<sub>6</sub>S 403.0337; found 403.0331.

3,8-Dihydroxy-2-methyl-1-(trifluoromethylsulfonyloxy)carbazole-5carbaldehyde (20b): To a solution of triflate 19b (64 mg, 0.14 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added BBr<sub>3</sub> (136 µL, 1.39 mmol) at -78 °C. After stirring at room temperature for 5 h, the reaction mixture was poured into ice water. The mixture was extracted with EtOAc. The EtOAc phase was washed with water and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10 g; EtOAc/hexane, 4:6 v/v) to give 3-hydroxycarbazole 20b (54 mg, 99%) as a pale yellow solid; m.p. 266–268 °C (EtOAc/hexane). IR (ATR): v = 3200, 1650 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, [D<sub>6</sub>]DMSO):  $\delta$  = 2.28 (s, 3 H), 7.02 (d, J = 8.1 Hz, 1 H), 7.72 (d, J = 8.1 Hz, 1 H), 8.65 (s, 1 H), 10.00 (s, 1 H), 11.35 (s, 1 H), 11.39 (br. s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz,  $[D_6]DMSO$ ):  $\delta = 11.1, 110.2, 110.4, 116.3, 119.0, 121.2,$ 123.6, 124.1, 127.1, 130.9, 132.7, 133.2, 149.0, 150.3, 192.1 ppm. MS (EI):  $m/z = 389 \text{ [M]}^+$ . HRMS (EI): calcd. for  $C_{15}H_{10}F_3NO_6S$ 389.0181; found 389.0179.

2-Methyl-1-trifluoromethylsulfonyloxy-3,8-bis[(2-trimethylsilyl)ethoxymethyloxy|carbazole-5-carbaldehyde (21): To a solution of 3,8dihydroxycarbazole **20b** (115 mg, 0.30 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added SEMCl (157  $\mu$ L, 0.89 mmol) and *i*Pr<sub>2</sub>NEt (256  $\mu$ L, 1.48 mmol) with cooling by an ice-water bath. After stirring at room temperature for 12 h, the reaction mixture was quenched with aqueous NH<sub>4</sub>Cl. The resulting mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was washed with water and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10 g; EtOAc/hexane, 1:19 v/v) to give the oily SEM ether 21 (187 mg, 97%). IR (ATR):  $\tilde{v} = 1690, 1400, 1210, 1040 \text{ cm}^{-1}$ . <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 0.01$  (s, 9 H), 0.01 (s, 9 H), 0.99–1.08 (m, 4 H), 2.44 (s, 3 H), 3.88 (t, J = 8.3 Hz, 4 H), 5.43 (s, 2 H), 5.51 (s, 2 H), 7.29(d, J = 8.1 Hz, 1 H), 7.72 (d, J = 8.1 Hz, 1 H), 8.77 (br. s, 1 H),8.98 (s, 1 H), 10.18 (s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  $= -1.5 (3 \times), -1.4 (3 \times), 10.6, 18.1, 18.1, 66.7, 67.4, 93.6, 94.4, 109.3,$ 111.8, 116.5, 120.8, 122.2, 123.5, 126.3, 128.0, 131.0, 131.2, 131.6, 148.5, 149.6, 191.7 ppm. MS (EI):  $m/z = 649 \text{ [M]}^+$ . HRMS (EI): calcd. for  $C_{27}H_{38}NO_8SSi_2$  649.1809; found 649.1779.

1-Iodo-2,5-dimethylhex-1-ene (23a): To a solution of Cp<sub>2</sub>ZrCl<sub>2</sub> (608 mg, 2.08 mmol) in dry 1,2-dichloroethane (4 mL) was added Me<sub>3</sub>Al (15% in hexane, 4.46 mL, 6.24 mmol) at room temperature, and the resulting mixture was stirred at the same temperature for 20 min. A solution of 5-methyl-1-hexyne (22a, 0.274 mL, 2.08 mmol) in dry 1,2-dichloroethane (2 mL) was added, and the mixture was stirred at the same temperature for 12 h and then cooled to 0 °C. A solution of I<sub>2</sub> (633 mg, 2.50 mmol) in dry THF (4 mL) was added dropwise. After stirring at room temperature for 1 h, the reaction was poured into ice water, and the resulting mixture was filtered through a pad of Celite. The filtrate was extracted with EtOAc. The organic layer was washed with water and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 20 g; hexane) to give the oily alkenyl iodide 23a (390 mg, 79%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 0.89 (d, J = 6.6 Hz, 6 H), 1.26–1.35 (m, 3 H), 1.45–1.55 (m, 1 H), 1.83 (d, J = 1.1 Hz, 3 H), 2.20 (dt, J = 1.1, 7.7 Hz, 2 H), 5.86 (q, J = 1.1 Hz, 1 H) ppm. <sup>13</sup>C NMR  $(75 \text{ MHz}, \text{CDCl}_3): \delta = 22.4 (2 \times), 23.9, 27.5, 36.9, 37.5, 74.2,$ 148.5 ppm. MS (EI):  $m/z = 238 \text{ [M]}^+$ . HRMS (EI): calcd. for C<sub>8</sub>H<sub>15</sub>I 238.0218; found 238.0222.

**1-Iodo-2,5-dimethylhept-1-ene (23b):** The same procedure as above was carried out using (*S*)-(+)-5-methyl-1-heptyne (**22b**,<sup>[5,17]</sup> 300 mg, 2.72 mmol), Cp<sub>2</sub>ZrCl<sub>2</sub> (796 mg, 2.72 mmol), Me<sub>3</sub>Al (15% in hexane, 5.8 mL, 8.17 mmol), and I<sub>2</sub> (829 mg, 3.27 mmol) to give the oily alkenyl iodide **23b** (400 mg, 58%). [a]<sub>20</sub><sup>20</sup> = +13.1 (c = 0.05, MeOH). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 0.84–0.88 (m, 6 H), 1.07–1.49 (m, 5 H), 1.83 (d, J = 1.1 Hz, 3 H), 2.14–2.23 (m, 2 H), 5.86 (q, J = 1.1 Hz, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 11.3, 19.0, 23.9, 29.3, 33.9, 34.5, 37.2, 74.2, 148.6 ppm. MS (EI): m/z = 252 [M]<sup>+</sup>. HRMS (EI): calcd. for C<sub>9</sub>H<sub>17</sub>I 252.0375; found 252.0372.

**Pinacol (2,5-Dimethylhex-1-en-1-yl)boronate (3a):** A solution of alkenyl iodide **23b** (100 mg, 0.42 mmol) in dry DMSO (20 mL) was added to a stirred suspension of bis(pinacolato)diboron (106 mg, 0.42 mmol), KOAc (124 mg, 1.26 mmol), and PdCl<sub>2</sub>(dppf) [3 mg, 0.0042 mmol, dppf = 1,1'-bis(diphenylphosphanyl)ferrocene] in dry DMSO (20 mL) at room temperature, and then the mixture was heated at 80 °C for 1 h. After cooling to an ambient temperature, the reaction was quenched with aqueous NH<sub>4</sub>Cl, and the resulting mixture was stirred at the same temperature for 30 min. After filtering the mixture through a pad of Celite, the filtrate was extracted with EtOAc. The EtOAc layer was washed with water and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The



residue was purified by column chromatography (silica gel, 20 g; EtOAc/hexane, 1:19 v/v) to give the oily pinacol 1-alkenylboronate **3a** (48 mg, 48%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 0.87$  (d, J = 6.6 Hz, 6 H), 1.19–1.36 (m, 14 H), 1.49–1.57 (m, 1 H), 1.97 (s, 1 H), 2.09 (t, J = 7.7 Hz, 2 H), 5.11 (s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 21.2$ , 22.6 (2×), 24.9 (4×), 27.7, 36.9, 40.0, 82.6 (2×), 163.6 ppm. The carbon signal adjacent to boron was not observed because of low intensity.<sup>[19]</sup> MS (EI): m/z = 238 [M]<sup>+</sup>. HRMS (EI): calcd. for C<sub>14</sub>H<sub>27</sub>BO<sub>2</sub> 238.2104; found 238.2100.

**Pinacol (2,5-Dimethylhept-1-en-1-yl)boronate (3b):** The same procedure as above was carried out using alkenyl iodide **23b** (200 mg, 0.79 mmol), bis(pinacolato)diboron (201 mg, 0.79 mmol), KOAc (234 mg, 2.38 mmol), and PdCl<sub>2</sub>(dppf) (6 mg, 0.0079 mmol) to give the oily pinacol 1-alkenylboronate **3b** (101 mg, 53 %).  $[a]_D^{20} = +26.5$  (c = 0.05, MeOH). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 0.83-0.87$  (m, 6 H), 1.05–1.52 (m, 17 H), 1.98 (d, J = 1.1 Hz, 1 H), 2.01–2.12 (m, 2 H), 5.12 (d, J = 1.1 Hz, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 11.3$ , 19.1, 21.2, 24.9 (4×), 29.37, 34.1, 34.5, 39.7, 82.6 (2×), 163.7 ppm. The carbon signal adjacent to boron was not observed because of low intensity.<sup>[19]</sup> MS (EI): m/z = 252 [M]<sup>+</sup>. HRMS (EI): calcd. for C<sub>15</sub>H<sub>29</sub>BO<sub>2</sub> 252.2261; found 252.2258.

3-Ethoxy-1-(2,5-dimethylhex-1-en-1-yl)-8-methoxy-2-methylcarbazole-5-carbaldehyde (24a): To a stirred mixture of triflate 19a (100 mg, 0.23 mmol), Na<sub>2</sub>CO<sub>3</sub> (74 mg, 0.70 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (3 mg, 0.0023 mmol) in dry DMF (5 mL) was added a solution of pinacol 1-alkenylboronate 3a (166 mg, 0.70 mmol) in dry DMF (15 mL) at room temperature. The mixture was heated at 80 °C for 3 h and then was cooled to an ambient temperature. The mixture was quenched with aqueous NH<sub>4</sub>Cl, and the resulting mixture was stirred at the same temperature for 30 min. After filtration through a pad of Celite, the filtrate was extracted with EtOAc. The EtOAc phase was washed with water and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 5 g; EtOAc/hexane, 1:14 v/v) to give 1-alkenylcarbazole 24a (88 mg, 96%) as a pale yellow solid; m.p. 130–132 °C (Et<sub>2</sub>O/hexane). IR (ATR):  $\tilde{v} = 1660 \text{ cm}^{-1}$ . <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 1.01 (d, J = 6.6 Hz, 6 H), 1.49–1.57 (m, 9 H), 1.64–1.75 (m, 1 H), 2.28 (s, 3 H), 2.35 (t, J = 7.0 Hz, 2 H), 4.11 (s, 3 H), 4.26 (q, J = 7.0 Hz, 2 H), 6.33 (s, 1 H), 6.95 (d, J = 8.1 Hz, 1 H), 7.68 (d, J = 8.1 Hz, 1 H), 8.11 (br. s, 1 H), 8.58 (s, 1 H), 10.22 (s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 13.5, 15.1, 17.8, 22.6 (2×), 27.9, 37.2, 37.4, 55.8, 64.3, 103.9, 106.0, 118.9, 119.8, 121.6, 125.7, 126.5, 129.8, 130.7, 130.7, 133.6, 143.2, 150.4, 151.7, 192.0 ppm. MS (EI): m/z = 393 [M]<sup>+</sup>. HRMS (EI): calcd. for C<sub>25</sub>H<sub>31</sub>NO<sub>3</sub> 393.2304; found 393.2302.

3-Ethoxy-8-isopropoxy-1-(2,5-dimethylhex-1-en-1-yl)-2-methylcarbazole-5-carbaldehyde (24b): The same procedure as above was carried out using triflate 19b (20 mg, 0.44 mmol), Na<sub>2</sub>CO<sub>3</sub> (14 mg, 0.131 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (5 mg, 0.0044 mmol), and pinacol 1-alkenylboronate **3a** (31 mg, 0.131 mmol) to give 1-alkenylcarbazole **24b** (18 mg, 99%) as a pale yellow solid; m.p. 84-86 °C (EtOAc/hexane). IR (ATR):  $\tilde{v} = 1670 \text{ cm}^{-1}$ . <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta =$ 1.02 (d, J = 6.6 Hz, 6 H), 1.49–1.55 (m, 9 H), 1.68–1.76 (m, 1 H), 2.29 (s, 3 H), 2.37 (t, J = 7.9 Hz, 1 H), 4.26 (q, J = 7.0 Hz, 2 H), 4.86-4.94 (m, 1 H), 6.35 (s, 1 H), 6.93 (d, J = 8.0 Hz, 1 H), 7.64(d, J = 8.0 Hz, 1 H), 8.06 (br. s, 1 H), 8.58 (s, 1 H), 10.20 (s, 1)H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 13.5, 15.1, 17.7, 22.2  $(2\times)$ , 22.7  $(2\times)$ , 27.8, 37.3, 37.4, 64.3, 71.1, 105.5, 106.1, 119.3, 119.9, 121.5, 122.8, 125.2, 126.5, 130.6, 130.7, 133.5, 143.0, 148.9, 151.7, 191.9 ppm. MS (EI): m/z = 421 [M]<sup>+</sup>. HRMS (EI): calcd. for C<sub>27</sub>H<sub>35</sub>NO<sub>3</sub> 421.2617; found 421.2600.

1-(2,5-Dimethylhex-1-en-1-yl)-2-methyl-3,8-bis[(2-trimethylsilyl)ethoxymethyloxy]carbazole-5-carbaldehyde (25a): The same procedure as above was carried out using SEM ether **21** (75 mg, 0.12 mmol), Na<sub>2</sub>CO<sub>3</sub> (3 M solution, 115 µL, 0.35 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (1.39 mg, 0.0012 mmol), and pinacol 1-alkenylboronate **3a** (72 mg, 0.35 mmol) to give the oily 3,8-bis(OSEM)-1-alkenylcarbazole **25a** (61 mg, 86%). IR (ATR):  $\tilde{v} = 1680$ , 1060 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 0.01$  (s, 9 H), 0.02 (s, 9 H), 0.88–0.94 (m, 1 H), 0.99–1.10 (m, 10 H), 1.53 (s, 3 H), 1.64–1.76 (m, 2 H), 2.32 (s, 3 H), 2.36 (t, J = 7.3 Hz, 1 H), 3.88 (q, J = 8.4 Hz, 4 H), 5.42 (s, 2 H), 5.49 (s, 2 H), 6.34 (s, 1 H), 7.19 (d, J = 7.2 Hz, 1 H), 7.66 (d, J = 7.2 Hz, 1 H), 8.33 (br. s, 1 H), 8.70 (s, 1 H), 10.28 (s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = -1.4$  (6×), 13.7, 17.8, 18.1, 18.1, 22.6 (2×), 27.9, 37.2, 37.3, 66.3, 67.1, 93.5, 94.4, 108.2, 109.7, 118.9, 119.8, 121.5, 123.2, 126.3, 127.3, 129.5, 130.3, 134.4, 143.2, 148.0, 149.8, 191.7 ppm. MS (EI): m/z = 611 [M]<sup>+</sup>. HRMS (EI): calcd. for C<sub>34</sub>H<sub>53</sub>NO<sub>5</sub>SSi<sub>2</sub> 611.3462; found 611.3470.

1-(2,5-Dimethylhept-1-en-1-yl)-2-methyl-3,8-bis[(2-trimethylsilyl)ethoxymethyloxy]carbazole-5-carbaldehyde (25b): The same procedure as above was carried out using SEM ether 21 (75 mg, 0.12 mmol), Na<sub>2</sub>CO<sub>3</sub> (3 m solution, 115 µL, 0.35 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (1 mg, 0.0012 mmol), and pinacol 1-alkenylboronate **3b** (87 mg, 0.346 mmol) to give the oily 3,8-bis(OSEM)-1-alkenylcarbazole **25b** (60 mg, 83%).  $[a]_{D}^{20} = +7.1$  (c = 0.05, MeOH). IR (ATR):  $\tilde{v} = 1680$ , 1080 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta =$ 0.01 (s, 9 H), 0.02 (s, 9 H), 0.83–0.90 (m, 1 H), 0.94–1.09 (m, 10 H), 1.22–1.31 (m, 1 H), 1.41–1.51 (m, 2 H), 1.53 (d, J = 0.7 Hz, 3 H), 1.62–1.71 (m, 1 H), 2.31 (s, 3 H), 2.37 (t, *J* = 6.6 Hz, 1 H), 3.88 (q, J = 8.4 Hz, 4 H), 5.41 (s, 2 H), 5.49 (s, 2 H), 6.34 (s, 1 H), 7.20 (d, J = 8.1 Hz, 1 H), 7.66 (d, J = 8.1 Hz, 1 H), 8.29 (br. s, 1 H),8.68 (s, 1 H), 10.29 (s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  $= -1.5 (3 \times), -1.4 (3 \times), 11.5, 13.7, 17.8, 18.1, 18.1, 19.2, 29.4, 34.2,$ 34.9, 36.9, 66.3, 67.1, 93.4, 94.4, 108.1, 109.7, 119.0, 119.9, 121.5, 123.2, 126.3, 127.3, 129.5, 130.3, 134.4, 143.1, 148.0, 149.8, 191.6 ppm. MS (EI):  $m/z = 625 \text{ [M]}^+$ . HRMS (EI): calcd. for C35H55NO5SSi2 625.3619; found 625.3621.

1-(2,5-Dimethylhex-1-en-1-yl)-5-hydroxymethyl-2-methyl-3,8-bis[(2trimethylsilyl)ethoxymethyloxy]carbazole (26): To a solution of 3,8bis(OSEM)-1-alkenylcarbazole 25a (75 mg, 0.12 mmol) in dry toluene (1 mL) was added DIBAL-H (0.99 M in toluene, 247 µL, 0.25 mmol) with cooling by an ice-water bath. After stirring at room temperature for 20 min, the reaction mixture was poured into ice water. The mixture was filtered through a pad of Celite, and then the filtrate was extracted with EtOAc. The EtOAc phase was washed with water and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 5 g; EtOAc/hexane, 3:7 v/v) to give the oily 5-hydroxymethylcarbazole 26 (68 mg, 90%). IR (ATR):  $\tilde{v}$  = 3460, 1060 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 0.02$  (s, 9 H), 0.02 (s, 9 H), 1.00–1.06 (m, 10 H), 1.54 (t, J = 10.0 Hz, 5 H), 1.66– 1.75 (m, 1 H), 2.29 (s, 3 H), 2.34 (t, J = 7.7 Hz, 2 H), 3.86 (t, J = 8.1 Hz, 4 H), 5.18 (s, 2 H), 5.34 (s, 2 H), 5.38 (s, 2 H), 6.33 (s, 1 H), 7.01–7.07 (m, 2 H), 7.82 (s, 1 H), 8.36 (br. s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = -1.4$  (3×), -1.4 (3×), 13.5, 17.9, 18.1, 18.2, 22.6, 27.9, 37.3, 37.4, 64.1, 66.1, 66.7, 94.1, 94.6, 107.1, 109.9, 118.7, 119.1, 119.7, 121.9, 123.0, 125.3, 128.6, 130.6, 133.7, 142.9, 143.2, 150.2 ppm. MS (EI): m/z = 613 [M]<sup>+</sup>. HRMS (EI): calcd. for C<sub>34</sub>H<sub>53</sub>NO<sub>5</sub>SSi<sub>2</sub> 613.3619; found 613.3614.

**3,8-Dihydroxy-2-methyl-1-(2,5-dimethylhex-1-en-1-yl)carbazole-5carbaldehyde (27a):** To a solution of 3,8-bis(OSEM)-1-alkenylcarbazole **25a** (83 mg, 0.14 mmol) in dry HMPA (2 mL) was added TBAF (1 m in THF, 678  $\mu$ L, 0.68 mmol) at room temperature. The mixture was heated at 100 °C for 1 h and then was cooled to an ambient temperature. The mixture was quenched with water, and the resulting mixture was extracted with EtOAc. The EtOAc phase was washed with water and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 5 g; EtOAc/hexane, 1:1 v/v) to give 3,8-dihydroxycarbazole **27a** (34 mg, 71%) as a pale yellow solid; m.p. 248–250 °C (EtOAc/hexane). IR (ATR):  $\tilde{v} = 3430$ , 1650 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, [D<sub>6</sub>]DMSO):  $\delta = 0.97$  (d, J = 6.2 Hz, 6 H), 1.44 (s, 3 H), 1.51 (t, J = 7.7 Hz, 2 H), 1.60–1.69 (m, 1 H), 2.13 (s, 3 H), 2.28–2.33 (m, 2 H), 6.38 (s, 1 H), 6.91 (d, J = 8.1 Hz, 1 H), 7.61 (d, J = 8.1 Hz, 1 H), 8.39 (s, 1 H), 8.99 (s, 1 H), 10.03 (s, 1 H), 10.27 (s, 1 H), 10.78 (s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 13.7$ , 17.8, 22.6, 27.5 (2×), 36.74 (2×), 107.7, 109.0, 119.2, 119.6, 121.5, 121.8, 123.8, 123.8, 129.3, 131.3, 133.4, 141.5, 148.7, 149.3, 191.4 ppm. MS (EI): m/z = 351 [M]<sup>+</sup>. HRMS (EI): calcd. for C<sub>22</sub>H<sub>25</sub>NO<sub>3</sub> 351.1834; found 351.1804.

3,8-Dihydroxy-2-methyl-1-(2,5-dimethylhept-1-en-1-yl)carbazole-5carbaldehyde (27b): To a solution of 3,8-bis(OSEM)-1-alkenylcarbazole 25b (50 mg, 0.08 mmol) in dry HMPA (2 mL) was added TBAF (1 м in THF, 399 μL, 0.39 mmol) at room temperature. The mixture was heated at 100 °C for 1 h and then was cooled to an ambient temperature. The mixture was quenched with water, and the resulting mixture was extracted with EtOAc. The EtOAc phase was washed with water and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 5 g; EtOAc/hexane, 1:4 v/v) to give 3,8dihydroxycarbazole 27b (20 mg, 67%) as a pale yellow solid; m.p. 222–224 °C (EtOAc/hexane).  $[a]_{D}^{20} = +20.0$  (c = 0.05, MeOH). IR (ATR):  $\tilde{v} = 3420, 1640 \text{ cm}^{-1}$ . <sup>1</sup>H NMR (300 MHz, [D<sub>6</sub>]DMSO):  $\delta$ = 0.91 (t, J = 7.2 Hz, 3 H), 0.96 (d, J = 6.1 Hz, 3 H), 1.18–1.27 (m, 1 H), 1.42–1.48 (m, 6 H), 1.61–1.68 (m, 1 H), 2.15 (s, 3 H), 2.27–2.35 (m, 2 H), 6.39 (s, 1 H), 6.92 (d, J = 7.9 Hz, 1 H), 7.62 (d, J = 7.9 Hz, 1 H), 8.39 (s, 1 H), 8.98 (s, 1 H), 10.04 (s, 1 H),10.24 (s, 1 H), 10.77 (br. s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, [D<sub>6</sub>]-DMSO):  $\delta = 11.3, 13.7, 17.8, 19.1, 28.9, 33.7, 34.3, 36.4, 107.7,$ 109.0, 119.3, 119.6, 121.5, 121.9, 123.8, 123.8, 129.3, 131.2, 133.3, 141.5, 148.7, 149.2, 191.4 ppm. MS (EI):  $m/z = 365 \text{ [M]}^+$ . HRMS (EI): calcd. for C<sub>23</sub>H<sub>27</sub>NO<sub>3</sub> 365.1991; found 365.1989.

Carbazomadurin A (1a): To a solution of 3,8-dihydroxycarbazole 27a (62 mg, 0.18 mmol) in MeOH was added NaBH<sub>4</sub> (8 mg, 0.22 mmol) at room temperature. After stirring at that temperature for 5 min, the reaction mixture was concentrated under reduced pressure. Water was added, and the resulting mixture was extracted with EtOAc. The organic layer was washed with water and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was recrystallized with chloroform/hexane to give carbazomadurin A (1a, 44 mg, 70%) as a pale yellow solid; m.p. 167-169 °C (CHCl<sub>3</sub>/hexane). IR (ATR):  $\tilde{v} = 3480, 3420, 1640, 1580,$ 1430, 1370 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>COCD<sub>3</sub>):  $\delta = 0.99$  (d, J = 6.2 Hz, 6 H), 1.55 (s, 3 H), 1.63–1.73 (m, 1 H), 2.25 (s, 3 H), 2.34 (t, J = 7.7 Hz, 2 H), 3.89 (t, J = 5.5 Hz, 1 H), 5.00 (d, J =5.9 Hz, 2 H), 6.42 (s, 1 H), 6.71 (d, J = 7.7 Hz, 1 H), 6.90 (d, J =7.7 Hz, 1 H), 7.57 (s, 1 H), 7.78 (br. s, 1 H), 8.35 (br. s, 1 H), 8.88 (br. s, 1 H) ppm. <sup>13</sup>C NMR (75 MHz, CD<sub>3</sub>COCD<sub>3</sub>):  $\delta$  = 13.6, 18.0, 22.9, 28.6, 37.8, 38.0, 63.9, 107.1, 109.7, 118.9, 120.4, 121.5, 122.4, 122.5, 123.7, 128.5, 130.6, 133.6, 133.7, 142.8, 143.0, 150.0 ppm. MS (EI):  $m/z = 353 \text{ [M]}^+$ . HRMS (EI): calcd. for  $C_{22}H_{27}NO_3$ 353.1991; found 353.1975.

(S)-(+)-Carbazomadurin B (1b): To a solution of 3,8-dihydroxycarbazole 27b (70 mg, 0.19 mmol) in MeOH (4 mL) was added NaBH<sub>4</sub> (9 mg, 0.23 mmol) at room temperature. After stirring at that temperature for 5 min, the reaction mixture was concentrated under reduced pressure. Water was added, and the resulting mixture was extracted with EtOAc. The organic layer was washed with water and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was recrystallized with CHCl<sub>3</sub>/hexane to give carbazomadurin B (1b, 55 mg, 78%) as a pale yellow solid, m.p. 166-167 °C (CHCl<sub>3</sub>/hexane); ref.<sup>[3]</sup> m.p. 108-110 °C; ref.<sup>[5]</sup> m.p. 165 °C.  $[a]_{D}^{20} = +13.1 \ (c = 0.05, \text{MeOH})$ . IR (ATR):  $\tilde{v} = 3480$ , 3430, 1630, 1580, 1430, 1370 cm<sup>-1</sup>. <sup>1</sup>H NMR (500 MHz,  $CD_3COCD_3$ ):  $\delta = 0.95$  (t, J = 7.3 Hz, 3 H), 1.00 (d, J = 6.1 Hz, 3 H), 1.22–1.29 (m, 1 H), 1.44–1.52 (m, 3 H), 1.57 (d, J = 1.2 Hz, 3 H), 1.68–1.74 (m, 1 H), 2.27 (s, 3 H), 2.32–2.43 (m, 2 H), 3.90 (t, J = 5.5 Hz, 1 H), 5.02 (d, J = 5.2 Hz, 2 H), 6.44 (s, 1 H), 6.74 (d, J = 7.6 Hz, 1 H), 6.93 (d, J = 7.6 Hz, 1 H), 7.60 (s, 1 H), 7.78 (br. s, 1 H), 8.37 (br. s, 1 H), 8.86 (br. s, 1 H) ppm. <sup>13</sup>C NMR (125 MHz,  $CD_3COCD_3$ ):  $\delta = 11.4, 13.2, 17.6, 19.1, 29.8, 34.7, 35.4, 37.2, 63.5,$ 106.8, 109.4, 118.6, 120.1, 121.2, 122.1, 122.2, 123.3, 128.2, 130.3, 133.4, 142.5, 142.6, 149.7 ppm. MS (EI): m/z = 367 [M]<sup>+</sup>. HRMS (EI): calcd. for C<sub>23</sub>H<sub>29</sub>NO<sub>3</sub> 367.2147; found 367.2154.

**Supporting Information** (see footnote on the first page of this article): Copies of the <sup>1</sup>H and <sup>13</sup>C NMR spectra of all compounds.

#### Acknowledgments

This work was supported in part by a Grant-in-Aid for Scientific Research (C) of the Japan Society for the Promotion of Science (grant number 17590025 for S. H.).

- a) H.-P. Husson, in: *The Alkaloids* (Ed.: A. Brossi), Academic Press, New York, **1985**, vol. 26, p. 1–51; b) P. Bhattacharya, D. P. Chakraborty, in: *Progress in Chemical and Organic Natural Products* (Eds.: W. Herz, H. Grisebach, G. W. Kirby, C. Tamm), Springer Verlag, Vienna, **1987**, vol. 52, p. 159–209; c) D. P. Chaktraborty, S Roys, in: *Progress in the Chemical and Organic Natural Products* (Eds.: W. Herz, H. Grisebach, G. W. Kirby, C. Tamm), Springer Verlag, Vienna, **1991**, vol. 57, p. 71–152; d) D. P. Chakraborty, in: *The Alkaloids* (Ed.: G. A. Cordell), Academic Press, New York, **1993**, vol. 44, p. 257–364; e) D. P. Chakraborty, S. Roy, in: *Progress in the Chemistry and Organic Natural Products* (Eds.: W. Herz, H. Grisebach, G. W. Kirby, W. Steglich, C. Tamm), Springer Verlag, Vienna, **2003**, vol. 69, p. 128–230.
- [2] a) H.-J. Knölker, K. R. Reddy, Chem. Rev. 2002, 102, 4303–4428; b) H.-J. Knölker, Top. Curr. Chem. 2005, 244, 115–148; c) H.-J. Knölker, K. R. Reddy, in: The Alkaloids (Ed.: G. A. Cordell), Academic Press, Amsterdam, 2008, vol. 65, p. 1–430; d) H.-J. Knölker, Chem. Lett. 2009, 38, 8–13; e) R. Forke, K. K. Gruner, K. E. Knott, S. Auschill, S. Agarwal, R. Martin, M. Böhl, S. Richter, G. Tsiavaliaris, R. Fedorov, D. J. Manstein, H. O. Gutzeit, H.-J. Knölker, Pure Appl. Chem. 2010, 82, 1975–1991; f) A. W. Schmidt, K. R. Reddy, H.-J. Knölker, Chem. Rev. 2012, 112, 3193–3328; g) I. Bauer, H.-J. Knölker, Top. Curr. Chem. 2012, 309, 203–254.
- [3] N. Kotoda, K. Shinya, K. Furihata, Y. Hayakawa, H. Seto, J. Antibiot. 1997, 50, 770–772.
- [4] H.-J. Knölker, J. Knöll, Chem. Commun. 2003, 1170-1171.
- [5] J. Knöll, H.-J. Knölker, Synlett 2006, 651–653.
- [6] a) T. Choshi, S. Hibino, *Heterocycles* 2011, *83*, 1205–1239; b) T. Choshi, S. Hibino, *Heterocycles* 2009, *77*, 85–97; c) T. Choshi, *Yakugaku Zasshi* 2001, *121*, 487–495; d) S. Hibino, E. Sugino, in: *Advances in Nitrogen Heterocycles* (Ed.: C. J. Moody), JAI Press, Greenwich, CT, 1995, vol. 1, p. 205–227; e) T. Kawasaki, M. Sakamoto, *J. Indian Chem. Soc.* 1994, *71*, 443–457.
- [7] a) T. Choshi, T. Sada, H. Fujimoto, C. Nagayama, E. Sugino, S. Hibino, *J. Org. Chem.* **1997**, *62*, 2535–2543; b) T. Choshi, T. Sada, H. Fujimoto, C. Nagayama, E. Sugino, S. Hibino, *Tetrahedron Lett.* **1996**, *37*, 2593–2596; c) T. Choshi, T. Sada, H. Fujimoto, C. Nagayama, E. Sugino, S. Hibino, *Heterocycles* **1996**, *43*, 1847–1854.



- [8] a) H. Hagiwara, T. Choshi, J. Nobuhiro, H. Fujimoto, S. Hibino, *Chem. Pharm. Bull.* 2001, *49*, 881–886; b) H. Hagiwara, T. Choshi, H. Fujimoto, E. Sugino, S. Hibino, *Chem. Pharm. Bull.* 1998, *46*, 1948–1949; c) H. Hagiwara, T. Choshi, H. Fujimoto, E. Sugino, S. Hibino, *Tetrahedron* 2000, *56*, 5807–5811.
- [9] a) S. Tohyama, T. Choshi, K. Matsumoto, A. Yamabuki, Y. Hieda, J. Nobuhiro, S. Hibino, *Heterocycles* 2010, 82, 397–416; b) S. Tohyama, T. Choshi, K. Matsumoto, A. Yamabuki, K. Ikegata, J. Nobuhiro, S. Hibino, *Tetrahedron Lett.* 2005, 46, 5263–5264; c) A. Yamabuki, H. Fujinawa, T. Choshi, S. Tohyama, K. Matsumoto, K. Ohmura, J. Nobuhiro, S. Hibino, *Tetrahedron Lett.* 2006, 47, 5859–5861; d) K. Matsumoto, T. Choshi, M. Hourai, Y. Zamami, K. Sasaki, T. Abe, M. Ishikura, N. Hatae, T. Iwamura, S. Tohyama, J. Nobuhiro, S. Hibino, *Bioorg. Med. Chem. Lett.* 2012, 22, 4762–4764; e) T. Abe, T. Ikeda, T. Choshi, S. Hibino, N. Hatae, E. Toyota, R. Yanada, M. Ishikura, *Eur. J. Org. Chem.* 2012, 5018–5027.
- [10] S. Tohyama, T. Choshi, S. Azuma, H. Fujioka, S. Hibino, *Heterocycles* 2000, 79, 955–965.
- [11] a) Y. Hieda, T. Choshi, Y. Uchida, H. Fujioka, S. Fujii, S. Hibino, *Chem. Pharm. Bull.* 2012, 60, 1522–1533; b) T. Choshi, Y. Uchida, Y. Kubota, J. Nobuhiro, M. Takeshita, T. Hatano, S. Hibino, *Chem. Pharm. Bull.* 2007, 55, 1060–1064.
- [12] Y. Hieda, T. Choshi, Y. S. Kishida, H. Fujioka, S. Hibino, *Tetrahedron Lett.* 2010, *51*, 3593–3596.

- [13] a) N. Miyaura, A. Suzuki, *Chem. Rev.* 1995, 95, 2457–2483; b)
  N. Miyaura, *Top. Curr. Chem.* 2002, 219, 11–58; c) K. Takahashi, J. Takagi, T. Ishiyama, N. Miyaura, *Chem. Lett.* 2000, 126–127; d) T. Oh-e, N. Miyaura, A. Suzuki, *Synlett* 1990, 221–223; e) N. Miyaura, T. Ishiyama, H. Hayashi, M. Ishikawa, M. Satoh, A. Suzuki, *J. Am. Chem. Soc.* 1989, 111, 314–321.
- [14] H. Suzuki, H. Gyoutoku, H. Yokoo, M. Shinba, Y. Sato, H. Yamada, Y. Murakami, Synlett 2000, 1196–1198.
- [15] G. C. Condie, M. F. Channon, A. J. Ivory, N. Kumar, D. S. Black, *Tetrahedron* **2005**, *61*, 4989–5004.
- [16] M. A. Kazankova, N. P. Protsenko, I. F. Lutsenko, Russ. J. Gen. Chem. 1968, 38, 106–108.
- [17] a) L. A. Aronica, S. Terreni, A. M. Caorusso, P. Salvadori, *Eur. J. Org. Chem.* **2001**, 4321–4329; b) L. Lardicci, C. Botteghi, E. Bendetti, *J. Org. Chem.* **1966**, *31*, 1543–1538.
- [18] a) D. E. van Horn, E. Negishi, J. Am. Chem. Soc. 1978, 100, 2252–2254; b) E. Negishi, D. E. van Horn, A. O. King, N. Okukado, Synthesis 1979, 501–502; c) C. L. Rand, D. E. van Horn, M. W. Moore, E. Negishi, J. Org. Chem. 1981, 46, 4097–4100; d) D. E. van Horn, E. Negishi, T. Yoshida, J. Am. Chem. Soc. 1985, 107, 6639–6647.
- [19] Y. Nishimura, Y. Okada, J. Jiao, M. Suetsugu, M.-T. Lan, M. Kinoshita, M. Iwasaki, K. Takagi, *Angew. Chem.* 2011, 123, 8819; *Angew. Chem. Int. Ed.* 2011, 50, 8660–8664.

Received: July 17, 2013

Published Online: September 20, 2013